About Faeth Therapeutics
Faeth Therapeutics is a publicly listed company based in San Francisco (United States) founded in 2019 by Oliver Maddocks and Anand Parikh, and was acquired by Sensei Biotherapeutics in February 2026. Personalized nutritional programs against cancer are provided. Faeth Therapeutics has raised $92 million across 3 funding rounds from investors including Khosla Ventures, Sensei Biotherapeutics and S2G Ventures. The company has 9 employees. Its chief executive, as recorded, is Anand Parikh. Faeth Therapeutics offers products and services including Faeth App and Clinical Trials. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Faeth Therapeutics Inc.
Company details
Faeth Therapeutics was founded in 2019 and is based in San Francisco, United States. Operations focus on the healthcare sector, specifically oncology through metabolic approaches. The Faeth program is offered as a precision treatment that targets cancer cell metabolism to limit growth and support standard therapies. Services include customized meals, therapeutics, and ongoing guidance from nutritionists for patients.
- Headquarters San Francisco, United States
- Employees 9
- Founders Oliver Maddocks, Anand Parikh
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website faeththerapeutics.com
- Social LinkedIn X
- Acquired by Sensei Biotherapeutics (Feb 2026)
- Legal Name Faeth Therapeutics, Inc.
- Net Profit-$21.09 M (USD)30.08as on Dec 31, 2025
- EBITDA-$22.15 M (USD)28.81as on Dec 31, 2025
- Total Equity Funding$92M (USD)
in 3 rounds
- Latest Funding Round$25M (USD), Series A
Oct 2025
- InvestorsKhosla Ventures
& 12 more
- Employee Count9
- Acquired bySensei Biotherapeutics
(Feb 2026)
Products & Services of Faeth Therapeutics
Faeth Therapeutics offers a comprehensive portfolio of products and services, including Faeth App and Clinical Trials.
Provides coaching and support for patients in clinical trials.
AI-driven programs targeting cancer metabolism for growth inhibition.
Funding Insights of Faeth Therapeutics
Faeth Therapeutics has successfully raised a total of $92M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $25 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $92M
- Total Rounds 3
- Last Round Series A — $25M
- First Round $20M
(Jan 2022)
- Investors Count 12
All 3 funding rounds of Faeth Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | $25M | Series A | – | S2G Investments | |
| Jun 2022 | $47M | Series A | – | S2G Ventures | |
| Jan 2022 | $20M | Seed | – | Khosla Ventures, Future Ventures |
13 investors in total: 13 institutional.
Investors in Faeth Therapeutics
Faeth Therapeutics has secured backing from 13 investors, including venture fund investors. Prominent investors backing the company include Khosla Ventures, Sensei Biotherapeutics and S2G Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Stage agnostic venture capital firm | s2gventures.com | Chicago, United States | ||
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Future Ventures is focused on early-stage venture capital investments. | future.ventures | Los Altos, United States | ||
Digitalis Ventures is engaged in health-focused investments. | digitalisventures.com | New York, United States | ||
Early-stage investments are made in frontier science ventures. | kdtvc.com | Black Mountain, United States | ||
Venture capital fund focused on ag-tech and food-tech sectors | agfunder.com | San Francisco, United States | ||
Seed stage tech-focused VC firm investing primarily in the US | cantos.vc | San Francisco, United States | ||
Venture capital firm focused on early-stage startups | unshackledvc.com | San Francisco, United States | ||
Multi-stage investment firm focused on venture and growth-stage businesses across food and agriculture, oceans, and energy | s2ginvestments.com | Chicago, United States | ||
Multistage investments are directed toward technology, healthcare, and climate sectors. | b.capital | Manhattan Beach, United States |
Investor details for Faeth Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Faeth Therapeutics
17 people are tracked at Faeth Therapeutics (10 in leadership, 3 in board & advisors, 4 in team); the tracked headcount is 9.
| Name | Role | Group |
|---|---|---|
Oliver Maddocks | Co-Founder | Leadership |
Anand Parikh | Founder & CEO | Leadership |
Lew Cantley | Director Meyer Cancer Center, Weill Cornell Medicine | Leadership |
Debbie Chirnomas | Chief Medical Officer | Leadership |
Dmitriy Rokhfeld | Chief Of Staff To The Chief Medical Officer | Leadership |
Simon Knott | Assistant Professor, Biomedical Sciences & Associate Director, Center for Bioinformatics and Functional Genomics, | Leadership |
Michael G. | Head of Regulatory Affairs | Leadership |
Thomas Strack | Chief Medical Officer | Leadership |
Juan Andrés Jelf | Associate Director Clinical Operations | Leadership |
Alan Sun | Vice President Of Product | Leadership |
Ralph Deberardinis | Advisor | Board & advisors |
Matthew Vander Heiden | Advisor | Board & advisors |
Heather Christofk | Advisor | Board & advisors |
Domen Kampjut | Associate Principal Scientist | Team |
Jonathan Lindström | Computational Biologist | Team |
Daniel Pennington | Clinical Trial Manager | Team |
Petros Tyrakis | Associate Principal Scientist | Team |
Complete people profiles for Faeth Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Faeth Therapeutics
Faeth Therapeutics is a publicly listed company on the NASDAQ with ticker symbol FTH in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 Feb 2021
- Listed onNASDAQ: FTH
- Listed entityFaeth Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS81728A2078
- Share price$21.51 (-7.48% on the day) · 2026-10-13
- Market capitalisation$555.8M
- EPS (diluted, trailing year)$-141.65
- Volume (last session)350,378
Financials of Faeth Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$21.1M | -$22.1M | |
| 2024 | -$30.2M | -$31.1M | |
| 2023 | -$34.1M | -$36.5M | |
| 2022 | -$48.6M | -$47.3M | |
| 2021 | -$36.8M | -$36.8M |
Detailed financial statements for Faeth Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Faeth Therapeutics
5 dated milestones of Faeth Therapeutics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Faeth Therapeutics is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $20.0M.
- Funding Latest funding round, Series A, of $25.0M.
- Exit Acquired by Sensei Biotherapeutics.
Web traffic of Faeth Therapeutics
The website of Faeth Therapeutics (faeththerapeutics.com) receives about 2.8K visits a month.
- Monthly visits2.8K
▼ 16.8% vs previous month
Top companies in Oncology
3 companies that operate in the same segment as Faeth Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Faeth Therapeutics
Complete news archive for Faeth Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Faeth Therapeutics
Faeth Therapeutics was founded in 2019 and raised its 1st funding round 3 years after it was founded.
Faeth Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Anand Parikh is the CEO of Faeth Therapeutics, as recorded in our data. They have also founded this company.
Faeth Therapeutics is a funded company, having raised a total of $92M across 3 funding rounds to date. The company's 1st funding round was a Seed of $20M, raised on Jan 2022.
Faeth Therapeutics has 9 employees.
Faeth Therapeutics was founded in 2019 and is based in San Francisco, United States. Operations focus on the healthcare sector, specifically oncology through metabolic approaches. The Faeth program is offered as a precision treatment that targets cancer cell metabolism to limit growth and support standard therapies. Services include customized meals, therapeutics, and ongoing guidance from nutritionists for patients.
Faeth Therapeutics offers Faeth App and Clinical Trials.
Yes, Faeth Therapeutics is publicly traded on NASDAQ under the ticker symbol FTH.
Faeth Therapeutics has 13 investors. Key investors include Khosla Ventures, Sensei Biotherapeutics, S2G Ventures, Future Ventures, and Digitalis Ventures.
Faeth Therapeutics operates through Faeth Therapeutics Inc..
Yes. Faeth Therapeutics was acquired by Sensei Biotherapeutics in February 2026.